Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells

被引:25
作者
Boyer, MW
Waller, EK
Bray, RA
Unangst, T
Johnson, TS
Phillips, C
Jurickova, I
Winton, EF
Yeager, AM
机构
[1] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Med, Atlanta, GA 30322 USA
[3] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA
关键词
acute myeloid leukemia; antigen presenting cells; costimulation;
D O I
10.1038/sj.leu.2401685
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Acute myeloid leukemia (AML) cells are malignant counterparts of normal myeloid pathway progenitors. Myeloid progenitors differentiate into professional antigen presenting cells (APC) under the essential influence of GM-CSF along with additional cytokines. Twelve cases of human AML were tested for ability to be differentiated toward a professional APC phenotype in short-term culture with addition of GM-CSF and the following recombinant proteins: TNF alpha, IL-4, CD40 ligand, Flt3 ligand and SCF. Significant upregulation of CD80 (B7-1) and enhancement of alloantigen presentation was seen with the addition of GMCSF and TNF alpha alone or with additional cytokines. The combination of GM-CSF and TNF alpha, either alone or in combination with an additional cytokine, resulted in enhancing alloantigen presentation by at least two-fold over the media control group in 10/12 patients studied, and resulted in CD80 expression of greater than 15% in 11/12 patients studied. In AML cultures with GM-CSF and TNF alpha, coexpression of CD80 and either CD34 or an aberrant surface marker (CD56) was seen. In one case, sorted CD80(+) cells retained a characteristic cytogenetic marker and CD34 expression, proving their derivation from an AML precursor. These studies verify other reports of in vitro differentiation of human AML precursors into enhanced APC, suggesting that this phenomenon could be utilized for immunotherapy strategies aimed at enhancing presentation of leukemia antigens to T cells.
引用
收藏
页码:412 / 418
页数:7
相关论文
共 27 条
[11]   Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML [J].
DunussiJoannopoulos, K ;
Weinstein, HJ ;
Nickerson, PW ;
Strom, TB ;
Burakoff, SJ ;
Croop, JM ;
Arceci, RJ .
BLOOD, 1996, 87 (07) :2938-2946
[12]  
Hirano N, 1996, LEUKEMIA, V10, P1168
[13]   ROLE OF B7-1 IN MEDIATING AN IMMUNE-RESPONSE TO MYELOID-LEUKEMIA CELLS [J].
MATULONIS, UA ;
DOSIOU, C ;
LAMONT, C ;
FREEMAN, GJ ;
MAUCH, P ;
NADLER, LM ;
GRIFFIN, JD .
BLOOD, 1995, 85 (09) :2507-2515
[14]  
Pickl WF, 1996, J IMMUNOL, V157, P3850
[15]  
REID CDL, 1992, J IMMUNOL, V149, P2681
[16]   PROLIFERATING DENDRITIC CELL PROGENITORS IN HUMAN BLOOD [J].
ROMANI, N ;
GRUNER, S ;
BRANG, D ;
KAMPGEN, E ;
LENZ, A ;
TROCKENBACHER, B ;
KONWALINKA, G ;
FRITSCH, PO ;
STEINMAN, RM ;
SCHULER, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (01) :83-93
[17]   Expression of CD86 on human marrow CD34+ cells identifies immunocompetent committed precursors of macrophages and dendritic cells [J].
Ryncarz, RE ;
Anasetti, C .
BLOOD, 1998, 91 (10) :3892-3900
[18]  
SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO
[19]  
2-Y
[20]   Efficient Presentation of Soluble Antigen by Cultured Human Dendritic Cells Is Maintained by Granulocyte/Macrophage Colony-stimulating Factor Plus Interleukin 4 and Downregulated by Tumor Necrosis Factor α [J].
Sallusto, Federica ;
Lanzavecchia, Antonio .
JOURNAL OF IMMUNOLOGY, 2018, 200 (03) :887-896